SELLAS Life Sciences (SLS) Liabilities and Shareholders Equity (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $114.2 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $114.2 million, up 226.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $276.4 million (up 187.86% YoY), and the FY2025 annual result was $78.3 million, up 303.18% from the prior year.
• Liabilities and Shareholders Equity grew to $114.2 million in Q1 2026 per SLS's latest filing, from $78.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $114.2 million in Q1 2026 and troughed at $6.2 million in Q4 2023.
• A 5-year average of $32.9 million and a median of $26.0 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity plunged 70.31% in 2023, then surged 303.18% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $20.9 million in 2022, then sank by 70.31% to $6.2 million in 2023, then surged by 212.46% to $19.4 million in 2024, then surged by 303.18% to $78.3 million in 2025, then soared by 45.74% to $114.2 million in 2026.
• Business Quant data shows SLS's Liabilities and Shareholders Equity at $114.2 million in Q1 2026, $78.3 million in Q4 2025, and $51.6 million in Q3 2025.